Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.34 |
| ▸ | GAA | P10253 | 3/20 | 0.34 |
| ▸ | GLA | P06280 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | EIF4A3 | P38919 | 2/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18520559 | 0.70 | NPC1 (0.57) | KDM4EALDH1A1HPGDNPC1RAB9A | |
| SCHEMBL12419266 | 0.70 | PIN1 (0.39) | FLT3PDGFRBKITKDM4EGAA | |
| SCHEMBL12641845 | 0.69 | ULK1 (0.46) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL12582027 | 0.67 | ULK1 (0.41) | KDM4EGAAGLAALDH1A1NPC1 | |
| SCHEMBL12596876 | 0.66 | GPR35 (0.53) | FLT3PDGFRBKITKDM4EGAA | |
| SCHEMBL16234632 | 0.65 | EIF4A3 (0.50) | KDM4ENPC1RAB9AEIF4A3KIF11 | |
| SCHEMBL12419264 | 0.64 | GPR35 (0.50) | FLT3PDGFRBKITKDM4EGAA | |
| SCHEMBL15223799 | 0.62 | KDM4E (0.46) | FLT3PDGFRBKITKDM4EGAA | |
| SCHEMBL22529402 | 0.62 | GRIN1 (0.72) | KDM4EHPGDEIF4A3GRIN1 | |
| SCHEMBL16234661 | 0.62 | EIF4A3 (0.51) | FLT3KDM4EALDH1A1HPGDEIF4A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | FLT3 1564/4885PDGFRB 2166/4885KIT 1868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.